Home > Insider Trading > Filing (0001209191-12-049852)

Filing Details

Accession Number:: 0001209191-12-049852
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2012-10-17 18:35:21
Reporting Period:: 2012-10-15

Filing Date:: 2012-10-17
Accepted Time:: 2012-10-17 18:35:21
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1338042	Aegerion Pharmaceuticals Inc.	AEGR	Pharmaceutical Preparations (2834)	202960116

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1198321	Farah Champsi	One Embarcadero Center Suite 3700 San Francisco CA 94132	No	No	Yes	No
1198332	Edward Penhoet	One Embarcadero Center, Suite 3700 San Francisco CA 94111	No	No	Yes	No
1211840	Edward Hurwitz	One Embarcadero Center, Suite 3700 San Francisco CA 94111	No	No	Yes	No
1257444	Alta Biopharma Partners Iii Lp	One Embarcadero Center Suite 3700 San Francisco CA 94111	No	No	Yes	No
1280234	Alta Biopharma Management Iii Llc	One Embarcadero Center Suite 3700 San Francisco CA 94111	No	No	Yes	No
1280238	Alta Embarcadero Biopharma Partners Iii Llc	One Embarcadero Center Suite 3700 San Francisco CA 94111	No	No	Yes	No
1280265	Alta Biopharma Partners Iii Gmbh & Co Beteiligungs Kg	One Embarcadero Center Suite 3700 San Francisco CA 94111	No	No	Yes	No
1341637	Alison Kiley	One Embarcadero Center Suite 3700 San Francisco CA 94111	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2012-10-15	55,626	$17.54	2,408,426	No	4	S	Direct
Common Stock	Disposition	2012-10-16	128,229	$18.67	2,280,197	No	4	S	Direct
Common Stock	Disposition	2012-10-15	3,736	$17.54	161,742	No	4	S	Indirect	See footnote
Common Stock	Disposition	2012-10-16	8,611	$18.67	153,131	No	4	S	Indirect	See footnote
Common Stock	Disposition	2012-10-15	1,371	$17.54	59,350	No	4	S	Indirect	See footnote
Common Stock	Disposition	2012-10-16	3,160	$18.67	56,190	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote

Footnotes

On October 15, 2012, Alta BioPharma Partners III, L.P. ("ABPIII"), Alta BioPharma Partners III GmbH & Co. Beteiligungs KG ("ABMPIIIKG"), and Alta Embarcadero BioPharma Partners III, LLC ("AEBPIII") disposed of 55,626, 3,736 and 1,371 shares of the Issuer's Common Stock, respectively, on the public market at an average price of $17.54 per share. The range of sale prices for the transactions reported was $17.20 to $18.08 per share. The reporting persons undertake to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares sold at each separate price.
These securities are beneficially owned by ABPIII.
Alta BioPharma Management III, LLC ("ABMIII") is the general Partner of ABPIII, the managing limited partner of ABPIIIKG. Farah Champsi, Edward Penhoet, and Edward Hurwitz are directors of ABMIII and managers of AEBPIII, along with ABPIII and ABPIIIKG shall be known as "the Funds," exercise shared voting and investment power with respect to the securities held by the Funds. Alison Kiley is a member of ABM III. Each of the reporting persons disclaim beneficial ownership of such securities, except to the extend of his, her, or its proportionate pecuniary interest herein.
On October 16, 2012, ABPIII, ABMPIIIKG, and AEBPIII disposed of 128,229, 8,611 and 3,160 shares of the Issuer's Common Stock, respectively, on the public market at an average price of $18.67 per share. The range of sale prices for the transactions reported was $18.20 to $19.23 per share. The reporting persons undertake to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares sold at each separate price.
These securities are beneficially owned by ABPIIIKG.
These securities are beneficially owned by AEBPIII.